Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   April 2011
 
A LA UNE
2011/04/26 - Lyonbiopole carries out its Sepsis program to fight against severe infectious conditions in collaboration with the 3 University Hospitals of the Rhône-Alpes region

The new program around severe infectious conditions has begun in April 2010 under the name: Sepsis program. It aims at gathering the key players of the Rhône-Alpes region around one topic :"sepsis”, the first cause of death in intensive care units, setting up and promoting R&D collaborative projects. Sepsis program aims at improving sepsis coverage and decreasing mortality. This program is based on a regional clinical network composed by the Rhône-Alpes clinical intensive care units of University Hospital of Grenoble, Lyon and St. Etienne, that gathered every year more than 1,300 patients affected by sepsis.
Contact: Pauline Cottin, Sepsis Program Coordinator - pauline.cottin@lyonbiopole.com

Learn more


2011/04/11 - Next: Lyonbiopole events in one click

Lyonbiopole has launched a new information tool, sent each Monday, dedicated to events organized by Lyonbiopole. Called “NEXT", this new electronic bulletin is dedicated to Lyonbiopole's members, companies and laboratories of Rhone-Alpes region. It summarizes all upcoming events organized by Lyonbiopole and give to the reader the opportunity to register with one click! This e-mailing includes all Lyonbiopole's events such as "Lunch Break Partnering", "Taste of Innovation" workshops, international trade missions...
Contact : Emilie Roméo, Project Manager - emilie.romeo@lyonbiopole.com


ZOOM SUR
Amoéba

Amoéba is an innovating company which develops, manufactures and markets biological disruptive products and services for the treatment of Legionella, amoeba and biofouling in water. Its solutions open a new way of biological treatment of the Legionella and amoebic risk for the industrials companies. Amoéba is one of the unique actors on the market to ensure amoebic analyses in water for industrials companies and the collectivity.

Learn more



A LA UNE
2011/06/27 - Registration to the 5th edition of Fast Track R&D Partnering with France (FTRD) on the occasion of BIO Washington

In Opening BIO Washington, on Monday, June 27th, 2011, Lyonbiopole organizes the 5th edition of the Fast Track R&D Partnering with France (FTRD), in partnership with UbiFrance and French Biotech Clusters, and with the support of DGCIS (French Government). Each year, this networking moment allows international companies to build new contacts and to present strategic partnership opportunities. Registration is now open.
Contact : Isabelle Scarabin, Economic and International Affairs Director - isabelle.scarabin@lyonbiopole.com / Kevin Romani, International Project Manager - kevin.romani@lyonbiopole.com

Learn more


2011/06/27 - BIO 2011 International Convention, the World Life Sciences Congress will be held on June, from 27th to 30th, 2011 in Washington DC.

The event, held annually in a major city in the United States or Canada, is organized by the "Biotechnology Industry Organization" (BIO). At BIO, Lyonbiopole will welcome attendees on a French booth gathering regional players and co-exhibiting companies in Rhône-Alpes region. The joint booth is cofunded by the Rhône-Alpes Region, the Greater Lyon, Metro of Grenoble and Aderly and in partnership with the Lyon Chamber of Commerce and UbiFrance.
Contact: Isabelle Scarabin, Economic and international Affairs Director - isabelle.scarabin@lyonbiopole.com / Kevin Romani, International Project Manager  - kevin.romani@lyonbiopole.com

Learn more


2011/09/18 to 2011/09/23 - Save the date: participate to a collective mission on « Infectious diseases and Immunology »

This mission will be held from 18th to 23rd of September 2011 on the US East Coast. It is addressed to every French biotech company that works on infectious diseases and immunology (drug discovery/development, vaccines, biotherapies, diagnostics, CRO/CMO, technology transfer) willing to develop industrial and technological partnerships with US partners. The mission results from a collaboration between the French Biotech Competitiveness Clusters and is coordinated by Lyonbiopole, the French Ministry of Industry, Ubifrance (French and American offices).
Contact: Kevin Romani, International Project Manager - kevin.romani@lyonbiopole.com

Learn more


2011/09/15 to 2011/09/16 - The 3rd edition of European Cancer Cluster Partnering will be held in Toulouse

ECCP is a Business to Business event, focused on oncology and dedicated to companies and bioclusters specialized in cancer. This event gathers business conventions, conferences, round tables, company's presentations and networking events and bring together all kind of players: big pharma, SMBs, clinicians, researchers, funders and bioclusters. ECCP is organized by two European cluster dedicated to cancer: Cancer-Bio-Santé of Toulouse and Oslo Cancer Cluster.

Learn more


2011/09/26 to 2011/09/28 - The Fondation Mérieux organizes a symposium devoted to "Vaccination and antibody: Prevention and therapy of nosocomial infections"

This meeting will focus on current knowledge about vaccines and immunotherapies for nosocomial infections. It will be held over three days at the Conference Center The Pensières at Veyrier du Lac.

Learn more


2011/10/09 to 2011/10/12 - Lyonbiopole partner of a Medtech and Biotech delegation organized by Erai in China

Population growth and ageing, improvement of standards of living ..., make health a major societal issue in China. This mission will allow to discover the activitiy of China in the field of health through the visit of the Zhangjiang Hi-Tech Park, a special day dedicated tothe promotion  of biotechnology and medical technology in Rhône-Alpes, the  visit of the BIO China International Convention and an individual BtoB program.
Contact: Kevin Romani, International project manager - kevin.romani@lyonbiopole.com

Learn more



AGENDA
Next Life Science events:
     
14th edition of 4i Forum
May 19th, 2011, Centre de congrès du WTC Grenoble
5th edition, Fast-Track R&D Partnering with France
June 27th, 2011, Washington DC
BIO International Convention,
June from 27th to 30th, 2011, Washington DC
ECCP Partnering - European Cancer Cluster Partnering
From September 14th to 16th 2011, Toulouse
Competitiveness clusters mission: infectious diseases (ICAAC, French Biotech Tour)
September from 18th to 23th, 2011, Chicago / Boston
5th edition of Lyonbiopole Partnering days
October 7th, 2011, Lyon
Mission Techmed et Biotech
October from 9th to 12th, 2011, China
BIO China International Conference,
October 12th and 13th, 2011,Shanghai
Competitiveness clusters mission: Neuroscience 2011
November from 12th to 16th, 2011, Washington DC
3rd edition, Private Investment Day
December 2nd, 2011, Lyon
 
A LA UNE
2011/04/29 - Next Eurostars call for projects

Lyonbiopole organizes a « Europe » workshop on April 29th, 2011, on the next Eurostars call for projects (next deadline for application: September 22th 2011).  This workshop is organized in 3 parts: the presentation of the program from 12:00 to 14:00 by Patrick Cornet (French Eurostars OSEO coordinator), exchanges with the speaker during lunch and individual confidential meetings from 14:00 to 18:00 with the speaker to discuss about a potential project.
Contact: Emilie Roméo, Project manager - emilie.romeo@lyonbiopole.com

Learn more


2011/05/19 - Information day about FP7 Cooperation Health Program

The FP7 National Contact Points organize in collaboration with the University Claude Bernard Lyon 1 and Lyonbiopole, an information day on upcoming funding opportunities within the priorities of the FP7 Health Program (upcoming call in July 2011)
Contact: Emilie Roméo, Project Manager - emilie.romeo@lyonbiopole.com

Learn more


2012/01/15 - Call for R&D Structuring Projects for competitiveness clusters

In the framework of « Future investments » program, the "R&D structuring projects of competitiveness clusters" call is permanently open until January 15th, 2012 on www.competitivite.gouv.fr. To be eligible for this call, your project must be a collaborative R&D project, accredited by a French competitiveness cluster, involving at least 2 companies and one laboratory or research centre. Lyonbiopole is at your entire disposal to support you to set-up your project and to study your applications for project accreditation.
Contact: Claudia Chagneau, Projects Manager -  claudia.chagneau@lyonbiopole.com

Learn more


2011/12/31 - Call for projects Strategic Industrial Sectors

Following the States-General of Industry and within the framework of future investments, a call for proposals to strengthen the competitiveness and efficiency of French strategic industrial sectors is open until December 31st, 2011. This call aims to support material or immaterial structural actions. The main objective should be to strengthen the competitiveness of industrial fields. The "Industry and health technologies" sector is part of 11 strategic industrial sectors selected.
Contact: Claudia Chagneau, Project Manager - claudia.chagneau@lyonbiopole.com

Learn more



A LA UNE
2011/04/18 - Lyonbiopole strengthens its links with hospital environment

Two new members have joined Lyonbiopole: the University Hospital of Grenoble and St. Etienne. With the Hospices Civiles de Lyon (HCL), Lyonbiopole has, among its members, the 3 largest Hospitals in the Rhone-Alpes region. They gather a total of 8,983 beds to 3,276 health professionals*. All the three University Hospitals are involved in the fight against infectious diseases in particular in the Sepsis program, coordinated by Lyonbiopole
Contact: Pauline Cottin, Sepsis Program Coordinator - pauline.cottin@lyonbiopole.com

* Sources: www.chu-grenoble.fr, www.chu-lyon.fr et www.chu-st-etienne.fr

Learn more


2011/05/27 - The 4th edition of Lyonbiopole's "investor meetings" will be dedicated to SHAM

These investor meetings will be organized in two different phases: individual meetings between member companies and the private investor and a workshop followed by a “networking buffet” in order to facilitate the exchange between investor and SMBs.
Contact: Kevin Romani, International Project Manager - kevin.romani@lyonbiopole.com

Learn more


2011/04/07 - Transgene's project on the development of therapeutic vaccine for the treatment of chronic hepatitis B infections was retained in the Coopol Innovation program

The France - China COOPOL Innovation program, launched in May 2008 by the Embassy of France in China (Beijing), offers cluster's innovative SMBs an assessment mission of the potential cooperation opportunities between French clusters and Chinese parks on R&D and training aspects. After PX'Therapeutics in 2010, Transgene benefits now from this program. Indeed, the Department of Infectious Diseases of Transgene is carrying an active program aiming at developing a therapeutic vaccine for the treatment of chronic hepatitis B infections which is among the 6th major health priorities in China (first national priority in infectious disease). The COOPOL-supported mission will allow to identify additional clinical partners able to contribute to the transversal immunological studies as well as potential manufacturers for the production of vaccine clinical lots.

Learn more


2011/04/19 - SynapCell signs a preclinical epilepsy research agreement with MedGenesis Therapeutix

Grenoble, France-based biotechnology firm SynapCell, which provides preclinical research on treatments for epilepsy, announces the signature of a preclinical epilepsy research agreement with MedGenesis Therapeutix Inc., which develops and commercializes innovative treatments for patients with serious neurological diseases. The research will use a new relevant model of chronic epilepsy to test MedGenesis Therapeutix’s lead product, GDNF, in combination with the company’s proprietary Convection Enhanced Delivery (CED) technology.

Learn more


2011/04/04 - Cystic fibrosis: Meveol effective against Burkholderia dolosa

Alaxia, a Lyon's biotech member of Lyonbiopole that is developing the candidate drug Meveol hired an independent certified laboratory to confirm in vitro efficacy recorded by its microbiologists. The effect of Meveol has been studied on several strains of Burkholderia dolosa. Meveol bactericidal efficacy - over 99.9% - is observed in a few hours. These results were obtained as part of a research partnership with Harvard Children's Hospital, Boston (USA), as Burkholderia dolosa affects their cystic fibrosis patients. This highly pathogen strain for CF patients is resistant to all known antibiotics.

Learn more


2011/04/19 - VIVALIS annouces the realization, with kaketsuken, human clinical studies with a vaccine candidate produced in EB6® cell

VIVALIS announces that the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) initiated the first human injection of an investigational influenza vaccine produced in EB66® cells in Japan. This program is part of the codevelopment and license agreement signed between GlaxoSmithKline (GSK) Biologicals and Kaketsuken, to co-develop seasonal and pandemic influenza vaccines produced using Vivalis’ EB66® cell line.

Learn more


2011/06/01 and 2011/06/02 - "New approaches for understanding of the human pathogenic viruses HCV and HIV in 21st Century" symposium

Prof. Jean-Luc Darlix and Dr. François-Loïc Cosset organized, with the support of the ENS, Foundation Finovi and Promega, a symposium on "New approaches for understanding human pathogenic viruses HIV and HCV in the twenty-first century". This event will be held on June 1st and 2nd 2011 at the Ecole Normale Superieure de Lyon.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |